Compare Incyte Corporation (INCY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oatly Group AB - ADR — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Incyte Corporation is far larger — about 69× Oatly Group AB - ADR's market cap, and Incyte Corporation is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Oatly Group AB - ADR for 18 Days on average.
| INCY | OTLY | |
|---|---|---|
Market Cap | $22.85B | $330.93M |
Volume | 1,927,029 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $15.91 |
52-Week Low | $83.80 | $8.03 |
Typical Hold Time | 33 Days | 18 Days |
Enterprise Value | $18.35B | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
OTLY trades at $10.38, up 0.1% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, showing progress toward profitability. The stock is supported by a consensus price target of $12.28 and positive news around Q2 2026 results, including a raised revenue outlook.
The outlook is cautiously optimistic as cost controls and sales growth may lead to positive EBITDA, but high debt and persistent cash burn pose risks. Analyst sentiment is mixed with 44% buy ratings, reflecting belief in the turnaround story amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
